JNCI Journal of the National Cancer Institute · 2006 · 164 citations · 27 references
MedicineOncologyPharmacologyCancer PharmacologyCancer PreventionMolecular OncologyChemical CarcinogenesisOncology PharmacologyRodent OncologyAnimal Model PharmacologyAnticancer ActivityLung CarcinogenesisLung Disease ProgressionLung GrowthMechanisms Of CarcinogenicityRodent Tumor BiologyRodent Tumor Models
BACKGROUND: Silibinin, a flavanone from milk thistle, inhibits the growth of tumors in several rodent models. We examined the effects of dietary silibinin on the growth, progression, and angiogenesis of urethane-induced lung tumors in mice. METHODS: A/J mice (15 per group) were injected with urethane (1 mg/g body weight) or saline alone and fed normal diets for 2 weeks, after which they were fed diets containing different doses of silibinin (0%-1% [wt/wt] silibinin) for 18 or 27 weeks. Immunohistochemistry and Western blot analysis were used to examine angiogenesis and enzymatic markers of inflammation, proliferation, and apoptosis. All statistical tests were two-sided. RESULTS: Urethane-injected mice exposed to silibinin had statistically significantly lower lung tumor multiplicities than urethane-injected mice fed the control diet lacking silibinin (i.e., control mice). Mice that received urethane and 1% (wt/wt) dietary silibinin for 18 weeks had 93% fewer large (i.e., 1.5-2.5-mm-diameter) lung tumors than control mice (mean number of tumors/mouse: 27 in the urethane group versus 2 in the urethane + 1% silibinin group, difference = 25 tumors/mouse, 95% confidence interval [CI] = 13 to 37 tumors/mouse, P = .005). Lung tumors of silibinin-fed mice had 41%-74% fewer cells positive for the cell proliferation markers proliferating cell nuclear antigen and cyclin D1 than lung tumors of control mice. Tumor microvessel density was reduced by up to 89% with silibinin treatment (e.g., 56 microvessels/400x field in tumors from control mice versus 6 microvessels/400x field in tumors from urethane + 1% silibinin-treated mice [difference = 50 microvessels/400x field, 95% CI = 46 to 54 microvessels/400x field; P<.001]). Silibinin decreased lung tumor expression of vascular endothelial growth factor (VEGF) and of inducible nitric oxide synthase and cyclooxygenase-2, two enzymes that promote lung tumor growth and progression by inducing VEGF expression. CONCLUSIONS: Silibinin inhibits lung tumor angiogenesis in an animal model and merits investigation as a chemopreventive agent for suppressing lung cancer progression.
27
Ahmedin Jemal, Thomas S. Murray, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2005 · 5.5K citations · Full text
TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION
Michael A. Gimbrone, Stephen B. Leapman, Ramzi S. Cotran et al. · The Journal of Experimental Medicine · 1972 · 900 citations · Full text
Medicine, Cancer Biology, Oncology +17
Benedetta Bussolati, Caroline Dunk, Malcolm Grohman et al. · American Journal Of Pathology · 2001 · 285 citations · Full text